Following on from information provided to NICE by the company in February 2017, the appraisal of Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy [ID1172] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1172 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 08 November 2022 | Discontinued. Following on from information provided to NICE by the company in February 2017, the appraisal of Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy [ID1172] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 29 March 2017 | Suspended. The Department of Health has asked us to conduct a Single Technology Appraisal of durvalumab for treating metastatic urothelial bladder cancer after chemotherapy. However, the company have advised that they will not be pursuing a licensing application for durvalumab from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme. As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes. |
For further information on our processes and methods, please see our CHTE processes and methods manual